Skip to main content
Fig. 6 | Cancer Nanotechnology

Fig. 6

From: Development of glycan-targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment

Fig. 6

STn-targeted NPs inhibit galectin-3 or ST6GalNAc-I in sTn-expressing tumor cells in vivo. ST6GalNAc-I (A, C) or galectin-3 (B, D) mRNA expression in MKN45-ST6GalNAc-I-derived tumors after intratumoral (A, B) or intravenous (C, D) injection of sTn-targeted NP (dsRNA-ST6GalNAc-I), sTn-targeted NP (dsRNA-galectin-3) or sTn-targeted NP (dsRNA-random). Values were normalized to β-actin. Data are the mean ± SEM, n = 3, *p < 0.05 and **p < 0.01

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us